Clinical trials: Stage III Rectal Cancer
Metastatic Colorectal Cancer (mCRC)
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
This is a two-arm, randomized, double-blinded, multicenter phase II/III clinical study to evaluate the safety and clinical efficacy of SHR-1701 or placebo in combination with BP102 (biosimilar to bevacizumab) and XELOX in…
- Trial name
- NCT04856787
- Testing
- SHR-1701、 BP102 、XELOX
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Colorectal Cancer
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic…
- Trial name
- NCT02788279
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Trial design: Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen. Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
- Trial name
- FOLF(HA)iri (NCT01290783)
- Testing
- Irintoecan, HA-Irinotecan solution for Infusion
- Where
- 5 sites in Australia
- Volunteers
- 390 people
- Sponsor
- Alchemia Oncology
Refractory Metastatic Colorectal Cancer
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants.
- Trial name
- NCT07361003
- Testing
- Suvemcitug injection, trifluridine/tipiracil tablets
- Where
- 6 sites in China
- Volunteers
- 464 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Colorectal Cancer
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type…
- Trial name
- NCT07595276
- Testing
- Enlituo®, Erbitux®
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Colorectal Cancer
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
The purpose of this study is to determine whether overall survival is prolonged in subjects with metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with cetuximab in combination with irinotecan…
- Trial name
- NCT00063141
- Testing
- cetuximab, Irinotecan
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 1,302 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer, Colon Cancer
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in patients with Metastatic Colorectal Cancer.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT00337389
- Testing
- 5- Fluorouracil (5-FU), bevacizumab (Avastin), Leucovorin
- Where
- 47 sites in United States, Serbia and Montenegro
- Volunteers
- 1,200 people
- Sponsor
- Mast Therapeutics, Inc.
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal…
- Trial name
- NCT00069108
- Testing
- 5 FU, Leucovorin, Oxaliplatin
- Where
- 87 sites in United States, Belgium and 18 more
- Volunteers
- 627 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms, Diarrhea
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
The triple combination chemotherapy of irinotecan, 5-fluorouracil and leucovorin (CPT-11/5-FU/LV or Saltz regimen) is the treatment of choice for patients with advanced colorectal cancer.
- Trial name
- NCT00036517
- Testing
- PHY906
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- PhytoCeutica
Metastatic Colorectal Cancer
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
This is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer.
- Trial name
- NCT04854668
- Testing
- Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin
- Where
- 92 sites in China
- Volunteers
- 748 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
This is a double-blind, randomized, multi-center, II/III study in at least 606 patients with advanced colorectal cancer. The study is being conducted to evaluate the safety of HR070803 combined with oxaliplatin, 5-FU/LV and…
- Trial name
- NCT05945901
- Testing
- HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- Where
- China
- Volunteers
- 669 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Neoplasms
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral).
- Trial name
- NCT00101686
- Testing
- Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab
- Where
- 175 sites in United States, Australia and 2 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Colorectal Cancer
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00016133
- Testing
- BCG vaccine, autologous tumor cell vaccine, fluorouracil
- Where
- 2 sites in United States
- Sponsor
- Intracel
Colorectal Cancer
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
- Trial name
- STELLAR-316 (NCT07750158)
- Testing
- Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa
- Where
- 13 sites in United States
- Volunteers
- 600 people
- Sponsor
- Exelixis
Symptomatic Colorectal Cancer, Advanced Colorectal Cancer
A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer
The primary objective of this study will be to assess how effective Xilonix is in the treatment of patients with symptomatic colorectal cancer.
- Conditions
- Symptomatic Colorectal Cancer, Advanced Colorectal Cancer, Colorectal Cancer With Cachexia
- Trial name
- NCT02138422
- Testing
- Xilonix
- Where
- Poland
- Volunteers
- 276 people
- Sponsor
- Janssen Research & Development, LLC
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Metastatic Colorectal Cancer (CRC)
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the…
- Trial name
- HARMONi-GI3 (NCT07228832)
- Testing
- Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
- Where
- 236 sites in United States, Belgium and 13 more
- Volunteers
- 600 people
- Sponsor
- Summit Therapeutics
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
The study is designed as phase III, randomized, two armed, parallel, double blind (patient and assessor blinded), active controlled, and equivalency clinical trial with primary endpoint of Progression-Free Survival of Cetuximab®…
- Trial name
- NCT03391934
- Testing
- Cetuximab + FOLFIRI
- Where
- Iran
- Volunteers
- 234 people
- Sponsor
- Cinnagen
Colorectal Neoplasms, Adenocarcinoma of the Colon
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX…
- Conditions
- Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT02425683
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- US Oncology Research
Cachexia
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.
- Trial name
- NCT00467844
- Testing
- GTx-024
- Where
- 52 sites in United States, Canada
- Volunteers
- 159 people
- Sponsor
- GTx